CRL

Business profile & competitive position

Charles River Laboratories International, Inc. (CRL) operates in the Healthcare sector, specifically the Medical – Diagnostics & Research industry. In plain terms, it is a full-service, non-clinical drug-development partner. Its clients, spanning biotechnology and pharmaceutical companies, use CRL from early target identification through non-clinical development and product release. The company reports through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. In 2025, total revenue was $4.0 billion, split 59.8% to DSA, 21.1% to RMS, and 19.1% to Manufacturing. The business currently runs more than 120 sites across more than 20 countries, giving it a globally distributed operating footprint.

Looking at the margin and return figures, the competitive picture is not one of a wide, cash-generating moat right now. The trailing net margin is -6.0%, and return on equity (ROE) is -7.7%. Those numbers mean the company is losing money on both an income-statement and an equity-return basis. A negative ROE of that size suggests that, at present, CRL is not producing positive economic returns for shareholders. The business still has strategic scale and an integrated portfolio—clients can buy research models, discovery services, safety assessment, and manufacturing support through one relationship—but the reported profitability does not yet validate a durable competitive advantage. Its beta of 1.40 also signals above-average sensitivity to broader market movements, which is consistent with a company whose earnings power is under pressure.

Financial posture

At a $14.5 billion market capitalization and a current share price of $300.02, CRL is priced as a sizable Healthcare name. The trailing P/E ratio is -62.0, which is not meaningful as a traditional valuation yardstick because the denominator is negative; it simply confirms that the company lost money on a trailing basis. With net margin at -6.0% and ROE at -7.7%, the current financial posture is one of negative profitability rather than stable, high-return earnings generation.

A market cap of $14.5 billion against $4.0 billion in 2025 revenue implies the market is applying a meaningful multiple to sales, but that multiple is being driven by expectations of a future recovery rather than by current earnings. Investors evaluating CRL therefore cannot rely on trailing P/E alone; they need to focus on forward estimates, free-cash-flow trajectory, and whether management’s restructuring actions can convert revenue back into profit. The 1.40 beta is also worth noting: the stock has historically moved more than the overall market, so volatility around earnings and macro headlines is likely to remain elevated.

Strategic priorities & outlook

CRL’s most recent 10-K filing lays out a clear operational agenda. First, the company plans to optimize its global footprint by closing or consolidating approximately 12 additional sites over the next two years, principally within the DSA and RMS segments. That move is aimed at taking cost and complexity out of the estate after a period of expansion. Second, it is integrating Discovery Services and Safety Assessment into one overarching DSA organization, with a combined sales force and leadership structure, so that clients see a single scientific partner rather than separate service lines. Third, the stated objective is to be the scientific partner of choice by delivering a comprehensive and integrated portfolio that accelerates biomedical research and therapeutic innovation. Fourth, CRL intends to continue expanding its Biologics Testing Solutions service offerings and facilities in the U.S. and Europe.

On the M&A front, the company acquired certain assets of K.F. (Cambodia) Ltd. in January 2026. That is a provider of non-human primates, and CRL said the assets support DSA supply operations and RMS third-party sales. That acquisition ties directly to the company’s reliance on research-model supply chains and its effort to secure inputs for its safety-assessment work.

Macro & geopolitical exposure

The Healthcare / Medical – Diagnostics & Research classification places CRL at the intersection of regulated science, global supply chains, and customer R&D budgets. Because much of its work is performed under GLP and non-GLP protocols, regulatory exposure is structural: changes in FDA, EMA, or OECD guidelines on non-clinical safety studies can alter study designs, timelines, and costs. Animal welfare regulations and import/export rules for non-human primates and other research models are also relevant, given the RMS business and the Cambodia acquisition.

Trade policy matters because CRL sources and moves biological products and research animals across borders. Any tightening of biosecurity, tariffs, or customs procedures could affect availability and cost. Currency risk is embedded in the model as well, with over 120 sites in more than 20 countries producing revenue and costs in multiple currencies. Client demand is tied to pharmaceutical and biotech R&D spending, which tends to fluctuate with interest rates, capital-market access, and drug-pipeline priorities. Finally, the business is exposed to the same supply-chain realities as other research-intensive industries: specialty reagents, animal feed, diagnostics kits, and logistics capacity can all influence margins and service levels.

Recent developments

Several near-term items are worth flagging from the news flow.

• On October 15, 2026, defenseworld.net noted that CRL’s share price crossed above its 200-day moving average.
• On October 13, 2026, Charles River announced a collaboration with Magellan Stem Cells to advance stem cell and regenerative medicine development.
• On October 9, 2026, the company scheduled its third-quarter 2026 earnings release and conference call.
• On October 7, 2026, Zacks published a piece comparing CRL and Progyny (PGNY) as value-stock candidates.

None of these headlines resolves the fundamental debate around profitability, but they do show three things: technical momentum watchers are paying attention to the 200-day average; the company is pursuing growth adjacencies such as regenerative medicine; and the third-quarter 2026 report on November 4 has become the next focal point for new data.

Earnings behavior & post-earnings drift

CRL has beaten EPS estimates in each of the last eight reported quarters, giving it a 100% beat rate over that span. The average earnings surprise across those eight quarters is 9.3%. That is a strong historical track record versus the market’s real expectation, but it also means expectations heading into each print are a high bar. The average 5-day price move after earnings over those quarters is +1.24%, classified as an upward post-earnings drift.

The recent quarterly history shows why averages can hide wide dispersion:

• August 5, 2026: actual EPS $3.02 vs. estimate $2.74, a 10.2% surprise. The stock rose 1.84% the next day and 9.07% over the following five days.
• May 7, 2026: actual EPS $2.06 vs. estimate $1.96, a 5.1% surprise. The stock fell 2.23% the next day and 12.42% over the following five days.
• February 18, 2026: actual EPS $2.39 vs. estimate $2.33, a 2.6% surprise. The stock rose 3.95% the next day and 6.05% over the following five days.
• November 5, 2025: actual EPS $2.43 vs. estimate $2.32, a 4.7% surprise. The stock rose 1.9% the next day and 2.27% over the following five days.

Three of the last four prints produced positive five-day moves, but the May 2026 quarter was a stark reminder that an earnings beat does not guarantee a bullish price response. Guidance, commentary on R&D demand, margin trajectory, and segment trends can all override the headline beat. The next scheduled report is November 4, 2026, before the market open, with a consensus EPS estimate of $2.97. At the time of writing, the stock is at $300.02, with RSI at 55.4 and the 50-day EMA at $282.51, indicating that it is neither deeply oversold nor overbought heading into the release.

For a deeper dive into the institutional view on CRL—including forward estimates, analyst models, and the full breakdown of strengths and risks—investors should examine the complete institutional verdict on the platform.